VIDEREGEN - Key Persons

Doug Quinn - CFO

Job Titles:
  • CFO
  • Chartered Management Accountant
  • Member of the Board and Management Team
Doug is a chartered management accountant and experienced finance director, having spent c.20 years working with start-up and early stage technology businesses. Alongside Videregen, Doug is part-time CFO with AIM listed SkinBioTherapeutics plc. Doug possess a wealth of experience in financial management, transactional and corporate governance, and has previously been involved in a number of M&A and AIM transactions.

Dr. Steve Bloor - CEO

Job Titles:
  • CEO
  • Member of the Board and Management Team
Steve has over 25 years' experience in the medical device and regenerative medicine industry. He has worked in US multinationals (J&J, Covidien) and UK start-up companies, with specific expertise in leadership roles. strategic R&D, clinical compliance and regulation. Steve was formerly CSO at Tissue Science Laboratories and was behind the development of TSL's tissue replacement technology. He subsequently became VP of R&D at Covidien following their $80m acquisition of TSL in 2008.

Martin Hunt

Job Titles:
  • Chairman of the Board and Management Team
Martin has >30 years' experience in large multi-nationals, start-ups and public companies with a strong track record of management success and fund raising (>£40m) in the life science sector. He is currently Programme Director of the NIHR programme Invention for Innovation (i4i) and a member of the NIHR Strategy Board, a provider of grant funding for health research, and was previously CEO of biomaterials Company Tissue Science Laboratories plc.